4577 — Daito Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥39bn
- ¥42bn
- ¥45bn
- 54
- 74
- 80
- 84
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 41,135 | 44,991 | 48,715 | 43,464 | 45,101 |
Cost of Revenue | |||||
Gross Profit | 8,671 | 9,479 | 10,798 | 11,459 | 10,331 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 36,610 | 39,652 | 43,005 | 37,166 | 39,920 |
Operating Profit | 4,524 | 5,340 | 5,710 | 6,298 | 5,181 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,619 | 5,595 | 5,874 | 6,720 | 5,076 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,496 | 3,925 | 4,157 | 4,628 | 3,527 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 3,513 | 3,945 | 4,246 | 4,668 | 3,599 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,513 | 3,945 | 4,246 | 4,668 | 3,600 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 256 | 281 | 292 | 316 | 229 |
Dividends per Share | |||||
Special Dividends per Share |